Citron Research Negative on NVIDIA (NVDA); Sees Stock Back to $90
Get Alerts NVDA Hot Sheet
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 0.1%
Revenue Growth %: +239.9%
Join SI Premium – FREE
Citron Research negative on NVIDIA (NASDAQ: NVDA), sees stock heading back to $90 in 2017.
The group cited six reasons:
1. Growth/Market Share: Much of NVDA's growth has come from gaming and at AMD's expense, as opposed to new total addressable markets
2. Data Center Competition: There's significant competition from existing and emerging players (Intel Xeon Phi, AMD Radeon Pro, XLNX). Also, AMD is launching new GPU's for desktop and server in Q1 2017 and Q2 2017.
3. Intellectual Property: If you beleive that NVDA has embedded IP that makes it worthy of its premium valuation, you need to be aware that Intel already has access to this IPO from a licensing deal with NVDA that ends this year.
4. Intel Licensing Revenue: Attrition will have a significant effect on 2017 EBITDA
5. Gross Margin Sustainability: As Intel competition enters the fray in mid-2017, this competition should have a significant impact on NVDA's gross margins. NVDA is a fabless producers, with TSMC making all of its GPUs. Intel, on the other hand, is vertically integrated. TSMC makes a 50% gross margins on NVDA's business, to which NVDA adds another 80% gross margin of its own. Intel could charge 37% less for its chips and still generate 80% gross margins.
6. Competition from Custom Silicon and GPU Workarounds: Competition from existing consumers (Google's TPU, Apple).
Citron readers know we have long been fans of $NVDA,but now the mkt is disregarding headwinds. In 2017 we will see $NVDA head back to $90 pic.twitter.com/n4U7f6eV7G
— Citron Research (@CitronResearch) December 28, 2016
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Active options: TSLA NVDA AMD AAPL MARA AMZN PLTR META
- STOXX 600 closes second-straight quarter with gains
- GE Vernova (GEV) and Solventum (SOLV) to Join S&P 500; Dentsply Sirona (XRAY) to Join S&P MidCap 400; Others to Join S&P SmallCap 600
Create E-mail Alert Related Categories
Short Sales, Trader TalkRelated Entities
Citron Research, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!